Company intelligence / Profile preview

FX Solutions

Ownership: Private
Development stage: Other

Overview

FX has developed innovative shoulder prosthetic devices and completed enrollment for an FDA Investigational Device Exemption study on its Easytech Reversed Stemless device—the first stemless reverse IDE completed in the US. Over 2,000 implants have been performed in Europe since 2015. The V135 platform received FDA 510(k) clearance and is commercially available[1][3].

Therapeutic areas: OtherRheumatology
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on FX Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FX Solutions.

Explore the full profile